Molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases to 1-1.5 Mb and preparation of a PAC-based physical map.

Loss of a whole chromosome 5 or a deletion of the long arm, del(5q), is a recurring abnormality in malignant myeloid diseases. In previous studies, we delineated a commonly deleted segment of approximately 4 Mb within band 5q31 that was flanked by IL9 on the proximal side and D5S166 on the distal side. We have generated a physical map of P1 (PAC), bacterial (BAC), and yeast artificial chromosome (YAC) clones of this interval. The contig consists of 108 clones (78 PACs, 2 BACs, and 28 YACs) to which 125 markers (5 genes, 11 expressed sequence tags, 12 polymorphisms, and 97 sequence-tagged sites) have been mapped. Using PAC clones for fluorescence in situ hybridization analysis of leukemia cells with a del(5q), we have narrowed the commonly deleted segment to 1-1.5 Mb between D5S479 and D5S500. To search for allele loss, we used 7 microsatellite markers within and flanking the commonly deleted segment to examine leukemia cells from 28 patients with loss of 5q, and 14 patients without cytogenetically detectable loss of 5q. In the first group of patients, we detected hemizygous deletions, consistent with the cytogenetically visible loss; no homozygous deletions were detected. No allele loss was detected in patients without abnormalities of chromosome 5, suggesting that allele loss on 5q is the result of visible chromosomal abnormalities. The development of a stable PAC contig and the identification of the smallest commonly deleted segment will facilitate the molecular cloning of a myeloid leukemia suppressor gene on 5q.

[1]  Iscn International System for Human Cytogenetic Nomenclature , 1978 .

[2]  J. Rowley,et al.  The Fourth International Workshop on Chromosomes in Leukemia: a prospective study of acute nonlymphocytic leukemia. Chicago, Illinois, U.S.A., September 2-7, 1982. , 1984, Cancer genetics and cytogenetics.

[3]  G. Tricot,et al.  The 5q-anomaly. , 1985, Cancer genetics and cytogenetics.

[4]  R. Larson,et al.  Clinical and cytogenetic correlations in 63 patients with therapy-related myelodysplastic syndromes and acute nonlymphocytic leukemia: further evidence for characteristic abnormalities of chromosomes no. 5 and 7. , 1986, Journal of clinical oncology : official journal of the American Society of Clinical Oncology.

[5]  S. Nimer,et al.  The 5q- abnormality. , 1987, Blood.

[6]  R. Larson,et al.  Specific chromosomal abnormalities in acute nonlymphocytic leukemia correlate with drug susceptibility in vivo. , 1988, Leukemia.

[7]  K. Sadhu,et al.  Human homolog of fission yeast cdc25 mitotic inducer is predominantly expressed in G2. , 1990, Proceedings of the National Academy of Sciences of the United States of America.

[8]  E. Green,et al.  Fluorescence in situ hybridization of YAC clones after Alu-PCR amplification. , 1992, Genomics.

[9]  R. Espinosa,et al.  Cytogenetic and molecular delineation of the smallest commonly deleted region of chromosome 5 in malignant myeloid diseases. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[10]  D. Liebermann,et al.  The zinc finger transcription factor Egr-1 is essential for and restricts differentiation along the macrophage lineage , 1993, Cell.

[11]  B. Johansson,et al.  Cytogenetic deletion maps of hematologic neoplasms: Circumstantial evidence for tumor suppressor Loci , 1993, Genes, chromosomes & cancer.

[12]  D. Oscier,et al.  Allelic loss of IRF1 in myelodysplasia and acute myeloid leukemia: retention of IRF1 on the 5q- chromosome in some patients with the 5q- syndrome , 1993 .

[13]  A. Knudson,et al.  Antioncogenes and human cancer. , 1993, Proceedings of the National Academy of Sciences of the United States of America.

[14]  al. et,et al.  Deletion of IRF-1, mapping to chromosome 5q31.1, in human leukemia and preleukemic myelodysplasia , 1993, Science.

[15]  A. Levine The tumor suppressor genes. , 1993, Annual review of biochemistry.

[16]  J. Boultwood,et al.  The 5q-syndrome. , 1994, Blood.

[17]  J. Rowley,et al.  Sequence-independent amplification and labeling of yeast artificial chromosomes for fluorescence in situ hybridization. , 1994, Cytogenetics and cell genetics.

[18]  V. Buckle,et al.  Molecular mapping of uncharacteristically small 5q deletions in two patients with the 5q- syndrome: delineation of the critical region on 5q and identification of a 5q- breakpoint. , 1994, Genomics.

[19]  J. Rowley,et al.  The balanced and the unbalanced chromosome aberrations of acute myeloid leukemia may develop in different ways and may contribute differently to malignant transformation. , 1994, Blood.

[20]  T. Rabbitts,et al.  Chromosomal translocations in human cancer , 1994, Nature.

[21]  P. Sanseau,et al.  Two simple procedures for releasing chromatin from routinely fixed cells for fluorescence in situ hybridization. , 1994, Cytogenetics and cell genetics.

[22]  P. Nowell,et al.  Physical mapping of the minimal region of loss in 5q- chromosome. , 1995, Proceedings of the National Academy of Sciences of the United States of America.

[23]  E. Green,et al.  Cytogenetic and molecular delineation of a region of chromosome 7 commonly deleted in malignant myeloid diseases. , 1996, Blood.

[24]  D. Le Paslier,et al.  A yeast artificial chromosome-based map of the region of chromosome 20 containing the diabetes-susceptibility gene, MODY1, and a myeloid leukemia related gene. , 1996, Proceedings of the National Academy of Sciences of the United States of America.

[25]  R. Larson,et al.  Therapy-related myeloid leukemia. , 2008, Seminars in oncology.

[26]  P. Deloukas,et al.  A Gene Map of the Human Genome , 1996, Science.

[27]  J. Massagué,et al.  A human Mad protein acting as a BMP-regulated transcriptional activator , 1996, Nature.

[28]  J. Karp,et al.  The secondary leukemias: challenges and research directions. , 1996, Journal of the National Cancer Institute.